See more : LD Intelligent Technology Co., Ltd (300883.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Inovio Pharmaceuticals, Inc. (INO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inovio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Desert Gold Ventures Inc. (DAU.V) Income Statement Analysis – Financial Results
- Loadstar Capital K.K. (3482.T) Income Statement Analysis – Financial Results
- StartEngine Crowdfunding, Inc. (STGC) Income Statement Analysis – Financial Results
- PT AKR Corporindo Tbk (AKRA.JK) Income Statement Analysis – Financial Results
- The Western Union Company (WU) Income Statement Analysis – Financial Results
Inovio Pharmaceuticals, Inc. (INO)
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 832.01K | 10.26M | 1.77M | 7.41M | 4.11M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.47M | 5.47M | 1.17M | 80.53K | 189.52K | 4.45M | 5.08M | 8.30M |
| Cost of Revenue | 3.50M | 5.50M | 4.73M | 94.25M | 88.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 225.00K | 206.25K | 0.00 | 0.00 | 0.00 | 1.93M | 1.46M | 1.20M |
| Gross Profit | -2.67M | 4.77M | -2.96M | -86.83M | -83.91M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.24M | 5.26M | 1.17M | 80.53K | 189.52K | 2.53M | 3.62M | 7.10M |
| Gross Profit Ratio | -321.09% | 46.44% | -166.56% | -1,171.66% | -2,040.54% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 93.51% | 96.23% | 100.00% | 100.00% | 100.00% | 56.77% | 71.29% | 85.54% |
| Research & Development | 86.68M | 187.65M | 249.24M | 94.25M | 88.02M | 95.26M | 98.57M | 88.71M | 57.79M | 34.10M | 21.37M | 17.98M | 20.03M | 13.26M | 9.41M | 5.75M | 9.63M | 8.51M | 11.45M | 6.55M | 2.15M | 2.47M | 459.71K | 6.98M | 8.10M |
| General & Administrative | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 0.00 | 5.61M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 6.62M | 5.61M | 5.50M |
| Other Expenses | -1.70M | -3.86M | 343.37K | 3.42M | 496.20K | 360.80K | 806.82K | 127.55K | 177.56K | 348.14K | -45.63M | 1.98M | 0.00 | 0.00 | 9.28M | 4,672.53B | 7,547.58B | 225.00K | 206.25K | 5.60M | 2.07M | 2.28M | 0.00 | 566.36K | 400.00K |
| Operating Expenses | 132.56M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 7.08M | 13.15M | 14.00M |
| Cost & Expenses | 144.77M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 9.01M | 14.61M | 15.20M |
| Interest Income | 8.13M | 4.78M | 3.36M | 3.31M | 2.61M | 2.26M | 1.61M | 1.40M | 305.07K | 0.00 | 132.21K | 166.11K | 0.00 | 0.00 | 0.00 | 0.00 | 1.27M | 867.07K | 207.68K | 247.56K | 65.50K | 32.32K | 443.63K | 556.19K | 556.19K |
| Interest Expense | 1.22M | 1.25M | 1.94M | 8.70M | 7.95M | 346.09K | 4.56M | 139.25K | 0.00 | 0.00 | 88.17M | 0.00 | 34.29K | 0.00 | 10.50M | 0.00 | 0.00 | 0.00 | 3.33M | 0.00 | 20.48K | 5.45K | -20.38K | 24.34K | 24.34K |
| Depreciation & Amortization | 3.50M | 5.50M | 4.73M | 4.63M | 5.52M | 5.00M | 3.47M | 3.09M | 1.92M | 1.57M | 2.10M | 1.99M | 2.01M | 2.11M | 1.68M | 993.03K | 954.64K | 911.64K | 799.32K | 573.04K | 584.41K | 619.34K | 0.00 | 566.36K | 400.00K |
| EBITDA | -130.39M | -270.90M | -296.56M | -149.56M | -107.34M | -89.80M | -84.74M | -74.15M | -33.37M | -37.93M | -19.45M | -22.65M | -21.64M | -17.11M | -13.96M | -11.97M | -10.19M | -12.43M | -11.38M | -10.94M | -6.05M | -5.28M | -5.58M | -8.37M | -8.97M |
| EBITDA Ratio | -15,671.81% | -2,616.89% | -16,528.13% | -1,027.76% | -2,567.66% | -293.47% | -196.54% | -212.84% | -85.14% | -366.03% | 179.60% | -626.01% | -301.08% | -318.79% | -120.85% | -606.13% | -382.00% | -358.53% | -147.17% | -937.17% | -7,511.39% | -2,787.69% | -125.22% | -164.87% | -81.93% |
| Operating Income | -135.23M | -267.57M | -301.22M | -124.08M | -111.11M | -94.09M | -83.64M | -76.24M | -34.28M | -39.50M | -19.54M | -23.49M | -21.64M | -19.22M | -13.96M | -13.66M | -15.90M | -13.35M | -15.51M | -11.51M | -6.63M | -5.93M | -5.58M | -9.53M | -6.90M |
| Operating Income Ratio | -16,253.01% | -2,607.35% | -16,972.34% | -1,674.25% | -2,702.10% | -308.68% | -198.11% | -215.55% | -84.50% | -377.71% | -145.12% | -570.42% | -220.91% | -312.79% | -153.04% | -651.14% | -330.68% | -384.82% | -283.63% | -986.27% | -8,237.11% | -3,131.53% | -125.22% | -187.79% | -83.13% |
| Total Other Income/Expenses | 109.31K | -10.08M | -2.01M | -38.81M | -9.70M | -706.88K | -4.56M | 2.50M | 3.08M | 3.36M | -46.54M | 3.78M | 6.33M | 1.51M | -10.50M | 692.84K | 3.42M | 867.07K | 2.44K | 247.56K | 6.63M | 26.87K | -3.29M | -597.18K | 2.93M |
| Income Before Tax | -135.12M | -277.65M | -303.22M | -162.89M | -120.81M | -94.80M | -88.21M | -73.74M | -31.20M | -36.14M | -66.08M | -19.71M | -12.95M | -17.71M | -24.46M | -13.61M | -12.48M | -14.48M | -15.50M | -0.66 | -0.43 | -5.91M | -8.87M | -10.13M | -6.60M |
| Income Before Tax Ratio | -16,239.87% | -2,705.57% | -17,085.39% | -2,197.89% | -2,938.01% | -311.00% | -208.92% | -208.49% | -76.90% | -345.61% | -490.69% | -478.63% | -132.19% | -288.27% | -268.21% | -648.80% | -259.52% | -417.65% | -283.59% | 0.00% | 0.00% | -3,117.36% | -199.11% | -199.55% | -79.52% |
| Income Tax Expense | 0.00 | 10.01M | 2.16M | 52.20M | -257.34K | 2.17M | 1.76M | -4.62M | -2.10M | -3.72M | 88.12M | -8.11M | -16.28M | -4.08M | 11.71M | -741.85K | -8.12M | -867.07K | 6.45M | -537.76K | -1.99M | 56.78K | 0.00 | 638.17K | -600.00K |
| Net Income | -135.12M | -287.66M | -305.38M | -215.09M | -120.55M | -96.97M | -88.21M | -73.74M | -29.19M | -36.12M | -66.03M | -19.67M | -15.25M | -17.61M | -24.41M | -12.97M | -11.20M | -12.48M | -15.30M | -10.97M | -4.66M | -5.96M | -8.87M | -9.60M | -6.60M |
| Net Income Ratio | -16,239.87% | -2,803.13% | -17,207.13% | -2,902.17% | -2,931.76% | -318.12% | -208.92% | -208.49% | -71.94% | -345.44% | -490.29% | -477.56% | -155.72% | -286.65% | -267.67% | -618.11% | -233.05% | -359.82% | -279.79% | -940.19% | -5,792.83% | -3,147.32% | -199.11% | -189.07% | -79.52% |
| EPS | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| EPS Diluted | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| Weighted Avg Shares Out | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.35M | 81.78M | 73.01M | 68.20M | 59.13M | 46.09M | 33.91M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
| Weighted Avg Shares Out (Dil) | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.54M | 81.92M | 73.21M | 68.37M | 59.41M | 46.09M | 34.13M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
Inovio Pharmaceuticals, Inc. (INO) Q3 2023 Earnings Call Transcript
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why
Inovio shares rise after positive FDA feedback on RRP treatment candidate
Source: https://incomestatements.info
Category: Stock Reports